Atea Pharmaceuticals, Inc. (AVIR) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 0.18
30Y Low0.2·High0.2
P/FCF
N/A
—
5yr avg: N/A
30Y Low11.6·High11.6
P/B Ratio
↓
1.64
↑+110% vs avg
5yr avg: 0.78
30Y Low0.5·High6.3
ROE
↓
-44.3%
↑-124% vs avg
5yr avg: -19.8%
30Y Low-69%·High19%
Debt/EBITDA
N/A
—
5yr avg: 0.00
30Y Low0.0·High0.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
AVIR Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Atea Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $433M | $291M | $282M | $254M | $400M | $789M | $3.4B | — | — |
| Enterprise Value | $338M | $196M | $219M | $113M | $-243174698 | $25M | $2.6B | — | — |
| P/E Ratio → | -2.86 | — | — | — | — | 6.53 | — | — | — |
| P/S Ratio | — | — | — | — | — | 2.25 | 70.82 | — | — |
| P/B Ratio | 1.64 | 1.06 | 0.64 | 0.46 | 0.63 | 1.11 | 6.29 | — | — |
| P/FCF | — | — | — | — | — | — | 11.61 | — | — |
| P/OCF | — | — | — | — | — | — | 11.61 | — | — |
P/E links to full P/E history page with 30-year chart
AVIR EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | 0.07 | 53.34 | — | — |
| EV / EBITDA | — | — | — | — | — | 0.18 | — | — | — |
| EV / EBIT | — | — | — | — | — | 0.18 | — | — | — |
| EV / FCF | — | — | — | — | — | — | 8.74 | — | — |
AVIR Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -44.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | 52.4% | 21.8% | — | — |
| Operating Margin | — | — | — | — | — | 39.4% | -22.7% | — | — |
| Net Profit Margin | — | — | — | — | — | 34.5% | -22.5% | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -44.3% | -44.3% | -33.9% | -22.7% | -17.2% | 19.3% | -3.9% | -68.9% | — |
| ROA | -40.6% | -40.6% | -31.8% | -21.6% | -16.1% | 14.8% | -2.5% | -47.3% | -26.0% |
| ROIC | -48.8% | -48.8% | -36.7% | -59.9% | — | — | — | — | — |
| ROCE | -50.1% | -50.1% | -38.3% | -27.1% | -19.2% | 21.9% | -3.9% | -55.4% | -28.6% |
AVIR Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $96M exceeds total debt of $843000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | 0.00 | — | — | — |
| Net Debt / Equity | — | -0.34 | -0.14 | -0.25 | -1.00 | -1.08 | -1.55 | -1.11 | — |
| Net Debt / EBITDA | — | — | — | — | — | -5.52 | — | — | — |
| Debt / FCF | — | — | — | — | — | — | -2.87 | — | — |
| Interest Coverage | — | — | — | — | -11.72 | — | — | — | — |
Net cash position: cash ($96M) exceeds total debt ($843000)
AVIR Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Atea Pharmaceuticals, Inc.'s current ratio of 7.82x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 18.24x to 7.82x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.82 | 7.82 | 24.85 | 18.24 | 35.77 | 13.58 | 2.73 | 9.00 | 19.71 |
| Quick Ratio | 7.82 | 7.82 | 24.85 | 18.24 | 35.77 | 13.58 | 2.73 | 9.00 | 19.71 |
| Cash Ratio | 7.59 | 7.59 | 24.44 | 17.86 | 35.00 | 13.44 | 2.69 | 8.90 | 19.60 |
| Asset Turnover | — | — | — | — | — | 0.45 | 0.06 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | 43.64 | — | — |
AVIR Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Atea Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 15.3% | — | — | — |
| FCF Yield | — | — | — | — | — | — | 8.6% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $81M | $84M | $83M | $83M | $88M | $82M | $83M | $10M |
Peer Comparison
Compare AVIR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 AVIRYou | $433M | -2.9 | — | — | — | — | -44.3% | -48.8% | — |
 IOVA | $1B | -3.3 | — | — | 97.2% | -153.1% | -55.5% | -48.9% | — |
 RDVT | $693M | 53.9 | 27.4 | 24.1 | 83.7% | 14.6% | 14.0% | 17.6% | 0.1 |
 RLAY | $2B | -7.8 | — | — | 76.8% | -1971.6% | -41.1% | -37.3% | — |
 COGT | $6B | -13.6 | — | — | — | — | -73.7% | -66.4% | — |
 ABUS | $838M | -25.6 | — | — | — | -271.0% | -38.5% | -47.1% | — |
 ACHV | $253M | -3.8 | — | — | — | — | -257.7% | — | — |
 GILD | $166B | 19.8 | 17.0 | 17.6 | 86.7% | 40.1% | 40.7% | 23.4% | 2.3 |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 MRK | $277B | 15.4 | 10.7 | 22.4 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 REGN | $74B | 17.1 | 17.8 | 18.1 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See AVIR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AVIR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AVIR vs IOVA
Side-by-side business, growth, and profitability comparison vs Iovance Biotherapeutics, Inc..
Start ComparisonAVIR — Frequently Asked Questions
Quick answers to the most common questions about buying AVIR stock.
What is Atea Pharmaceuticals, Inc.'s P/E ratio?
Atea Pharmaceuticals, Inc.'s current P/E ratio is -2.9x. The historical average is 6.5x.
What is Atea Pharmaceuticals, Inc.'s ROE?
Atea Pharmaceuticals, Inc.'s return on equity (ROE) is -44.3%. The historical average is -24.5%.
Is AVIR stock overvalued?
Based on historical data, Atea Pharmaceuticals, Inc. is trading at a P/E of -2.9x. Compare with industry peers and growth rates for a complete picture.